A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress

Kato K., Shah M., Enzinger P., Bennouna J., Shen L., Adenis A., ...More

ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, Spain, 20 - 23 June 2018, vol.29, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 29
  • City: Barcelona
  • Country: Spain
  • Istanbul University Affiliated: Yes